Michael Singer

Insider Reports History

Entity
Individual
Location
C/O Cartesian Therapeutics, Inc., 704 Quince Orchard Rd, Gaithersburg, MD
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Michael Singer
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Michael Singer:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Cartesian Therapeutics, Inc. Director Common Stock 96.2K $318K $3.30 Jan 2, 2025 as custodian
Cartesian Therapeutics, Inc. Director Common Stock 73.5K $243K $3.30 Jan 2, 2025 Direct
Cartesian Therapeutics, Inc. Director Common Stock 14.8K $48.8K $3.30 Jan 2, 2025 by spouse
Cartesian Therapeutics, Inc. Director Common Stock 7.13K $23.5K $3.30 Jan 2, 2025 by trust
Cartesian Therapeutics, Inc. Director Stock Option (Right to Buy) 7.8K $6.16K $0.79 Jan 2, 2025 Direct
Cartesian Therapeutics, Inc. Director Series A Non-Voting Convertible Preferred Stock 0 Apr 8, 2024 as custodian
Cartesian Therapeutics, Inc. Director Series A Non-Voting Convertible Preferred Stock 0 Apr 8, 2024 by spouse
Cartesian Therapeutics, Inc. Director Series A Non-Voting Convertible Preferred Stock 0 Apr 8, 2024 by trust
Cartesian Therapeutics, Inc. Director Series A Non-Voting Convertible Preferred Stock 0 Apr 8, 2024 Direct

Insider Reports Filed by Michael Singer

Symbol Company Period Transactions Value $ Form Type Date Filed Role
RNAC Cartesian Therapeutics, Inc. Jan 2, 2025 2 $0 4 Jan 6, 2025 Director
RNAC Cartesian Therapeutics, Inc. Dec 26, 2024 1 $0 4 Dec 30, 2024 Director
RNAC Cartesian Therapeutics, Inc. Nov 19, 2024 1 $0 4 Nov 21, 2024 Director
RNAC Cartesian Therapeutics, Inc. Apr 8, 2024 14 $0 4 Apr 10, 2024 Director
RNAC Cartesian Therapeutics, Inc. Dec 22, 2023 3 $0 4 Jan 4, 2024 Director, 10%+ Owner
SELB Cartesian Therapeutics, Inc. Nov 13, 2023 14 $0 4 Nov 15, 2023 Director, 10%+ Owner
SELB Cartesian Therapeutics, Inc. Nov 13, 2023 0 $0 3 Nov 15, 2023 Director, 10%+ Owner